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1. INTRODUCTION
An ideal dosage regimen in the drug therapy of any disease is the one,
which immediately attains the desire therapeutics concentration of drug in plasma
(or at the site of action) and maintains it constant for the entire duration of
treatment. This is possible through administration of conventional dosage form in
a particular dose and at a particular frequency. Thus drug may be administered by
variety of routes in a variety of dosage forms 1 .
Drugs are more frequently taken by oral administration. Although a few
drugs taken orally are intended to be dissolved within the mouth, the vast majority
of drugs taken orally are swallowed. Compared with alternate routes, the oral
route of drug administration is the most popular and has been successfully used
for conventional delivery of drug. It is considered most natural, uncomplicated,
convenient, safe means of administering drugs, greater flexibility in dosage form
design, ease of production and low cost2.
Tablets and hard gelatin capsules constitute a major portion of the drug
delivery systems that are currently available. However, many patient groups such
as elderly, children, and patients mentally retarded, uncooperative, nauseated, or
on reduced liquid intake diets have difficulty in swallowing these dosage forms.
Many elderly persons face difficulties in administering conventional oral dosage
forms because of hand tremors and dysphasia. Swallowing problem is common in
children because of their underdeveloped muscular and nervous systems. In some
cases like motion sickness, sudden episodes of allergic attack or coughing, and
during unavailability of water, swallowing conventional tablets is difficult. To
fulfill these medical needs, formulators have devoted considerable efforts for
developing a novel type of dosage form for oral administration known as  fast
water dispersible  tablet 3.
The past two decades, there has been enhanced demand for more patient
compliant dosage forms. As a result, the demand for the technologies has been
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increased 3 fold annually. Since the development cost of a new chemical entity is
very high, the pharmaceutical companies are focusing on the development of new
drug delivery systems for existing drug with an improved efficacy and
bioavailability together with reduced dosing frequency to minimize the side
effects.
Oral route of drug administration have wide acceptance up to 50-60% of
total dosage forms. Solid dosage forms are popular because of ease of
administration, accurate dosage, self medication, pain avoidance and most
importantly patient compliance. The most popular solid dosage forms are being
tablets and capsules one important draw back of these dosage forms is the
difficulty to swallow.
Tablet is the most popular among all dosage forms existing today because
of its convenience of self administration, compactness and easy manufacturing;
however hand tremors, dysphasia in case of geriatric patients, the underdeveloped
muscular and nervous systems in young individuals and in case of uncooperative
patients, the problem of swallowing is common phenomenon which leads to poor
patient compliancel.
Dysphagia or difficulty in swallowing is seen to afflict nearly 35% of
general population. This disorder is also associated with number of medical
conditions including Stroke, Parkinson's disease, AIDS, head and neck radiation
therapy and other neurological disorders including cerebral palsy. Many elderly
persons will have difficulties in taking conventional dosage forms (Solutions,
Suspensions, Tablets, Capsules) because of hand tremors, and dysphagia 3.
Swallowing problems are also common in young individuals because of
their under developed muscular and nervous systems. Other groups who may
experience problems in swallowing solid dosage forms, mentally ill, the
developmentally disabled, un co-operated patient and reduce liquid intake plans
or nausea. In some cases such as motion sickness sudden episodes of allergic
attack or coughing and unavailability of water, swallowing tablet may become
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difficult and consequently do not take medications as prescribed which results in
high incidence of noncompliance and ineffective therapy.
To fulfill these medical needs pharmaceutical technologists have devoted
considerable effort to develop a novel type of dosage form for oral administration,
the Fast water dispersible tablet , tablet that disintegrates and dissolves rapidly in
saliva without need of drinking water. The orodispersible tablet usually dissolves
in the oral cavity in about 10 seconds to 3 minutes. Faster the drug goes into
solution, the quicker absorption and onset of clinical effect. Some of the drugs are
absorbed from the mouth, pharynx and esophagus as the saliva passes down in to
the stomach, in such cases bioavailability of the drug of significantly greater than
those observed from conventional tablet dosage form. The development of
orodispersible also provides line extension in market place, product identity,
promotion in the sales in market place. These tablets are not only indicated for the
people who have swallowing difficulties, but also ideal for active people 3,4 .
The orally disintegrating tablets are also called as orodispersible tablets,
quick disintegrating tablets, fast disintegrating tablets, porous tablets, rapimelts.
However of all the above terms, United States Pharmacopoeia (USP) approved
these dosage forms as ODTs. Recently, European Pharmacopoeia has used the
term “orodispersible tablet” for tablets that disperse readily and within three
minutes before swallowing.
United States Food and Drug Administration (FDA) defined ODT as “A
solid dosage form containing medicinal substances or active ingredient which
disintegrates rapidly usually within a matter of seconds when placed upon the
tongue”. The disintegration time for ODTs generally ranges from several seconds
to about a minute5.
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1.1. ORODISPERSIBLE DOSAGE FORM
Mechanism of fast orodispersible tablet 1 , 4
Generally, an orodispersible tablet is a solid-dosage form that disintegrates
and dissolves in the mouth (either on or beneath the tongue or in the buccal
cavity) without water within 60 seconds or less.
"A solid dosage form containing medicinal substances, which disintegrates
rapidly, usually within a matter of seconds, when placed upon the tongue".
Generally, orodispersible tablets are  formulated  to  disperse  rapidly in
the   mouth, enabling  medication  to  be  swallowed  without  water,  thereby
increasing  convenience  and  compliance   across  a  broad  range  of indications
and   patient  types, including  the  young,  elderly,  and active  patients.
Following  dispersion, the  formulations  are  typically  swallowed,  and  the  drug
is  absorbed in  the  same  way  as  conventional  solid-oral  dosage  forms.
"However, orodispersible tablets  may  also  be  used  to  deliver  drugs
to  the  oral cavity,  for  local  action  or,  in  some  cases,  absorption  across  the
oral mucosa,  thereby  avoiding  first-pass  hepatic metabolism  and potentially
increasing  the  rate  and  extent  of  uptake,  and  reducing undesirable
metabolites.  The  potential  for  such pregastric  absorption  rests  largely  in  the
physicochemical characteristics  of  the  drug  molecule.  The  intrinsic  taste  of
the  drug is  also  a  significant  consideration  for  all orodispersible tablet
formulations
Challenges in orodispersible tablet 4
Although orodispersible tablet formulations offer benefits, there are
factors to consider. "The challenges of developing orodispersible tablet
formulations products are similar to those for conventional solid oral dosage
forms in terms of the need to establish compatibility of the active drug substance
with the excipients and process. "In addition, the intended oral dispersion of the
units means that the specific taste and mouthfeel characteristics of the drug
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substance are particularly relevant." Sweeteners and flavors are typically included
to achieve a palatable formulation, but additional taste-masking strategies may
also be required such as ion-exchange resins and active pharmaceutical ingredient
(API) encapsulation.
"Another challenge is that orodispersible tablet are potentially less robust
than conventional solid-oral dosage forms, given their formulation to achieve
rapid disintegration (eg. increased friability and greater moisture sensitivity), so
packaging requirements need to be considered early in the development process.
As for any other dose form, the bioavailability of orodispersible tablet is
governed by the physicochemical characteristics of the API and formulation
optimization. "The extent of pregastric formulation is largely dependent on the
physicochemical characteristics of the drug, but the formulation may aim to
maximize the potential to optimize bioavailability, or minimize the effect to
ensure bioequivalence with a per orally absorbed dosage form". Typical
formulation variables considered are solubility and particle size of the API,
formulation pH, and formulation constituents, in particular taste- masking agents.
Widening the scope of Orodispersible tablet 4
Industry observers point to broadening uses of orodispersible tablet
technology. These include the incorporation of macromolecules using
orodispersible tablet into vaccines. "The success for other peptide and protein
products will depend on bioavailability requirements and the application of
methods to overcome oral absorption barriers," Other areas include: the
incorporation of encapsulated APIs to achieve modified-release profiles within
the convenience of orodispersible tablet; and the further development of super
disintegrants for incorporation into conventional, compressed tablets, potentially
widening the opportunity for orodispersible tablet development to non specialist
companies.
Thin-film strip technology uses a range of water-soluble polymers and is
reported to be able to incorporate water-soluble, insoluble, or taste-masked
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ingredients. The film is manufactured as a continuous sheet and then cut into
individual doses prior to packing. The major limitations to this technology are the
relatively low doses that can be accommodated (approximately 30 mg) and its
moisture sensitivity requiring specific unit-dose packaging to protect the product
and ensure shelf life.
Advantages of the Orodispersible tablets for patients 1,4,5,6
 Ease of administration to the patient who can not swallow, such as the
elderly stroke victims, bed ridden patients, patients affected by renal failure
and who refuse to swallow such as pediatric, geriatric and psychiatric
patients.
 Rapid dissolution and absorption of the drug, which will produce quick
onset of action.
 Achieve increased bioavailability / rapid absorption through pre-gastric
absorption of drugs from the mouth, pharynx and esophagus as saliva passes
down.
 Convenient for administration and patient complaint for disabled, bedridden
patients and for travelers and busy people who do not always have access to
water.
 Good mouth feel property helps to change the perception of medication as
bitter pill particularly in pediatric patients.
 The risk of chocking of suffocation during oral administration of
conventional formulations due to physical obstruction is avoided, thus
providing improved safety.
 New business opportunity like product differentiation, product promotion,
patent extension and life cycle management.
Limitations of Orodispersible Tablet
 The tablets usually have insufficient mechanical strength. Hence, careful
handling is required.
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 The tablets may leave unpleasant taste and/or grittiness in mouth if not
formulated properly.
Counseling Points for Orodispersible tablet 1
Pharmacists are in the ideal position to become familiar with the different
technologies, and educate their patients on what to expect upon taking their first
dose. The majority of patients receiving Orodispersible tablet  preparations have
little understanding of this new dosage form. Patients may be surprised when
tablets begin to dissolve in the mouth. They might expect a faster onset of
therapeutic action. Clarification from the pharmacist can avoid any confusion or
misunderstanding. As with all dosage form technologies, some patient
populations are better served by their use than others. Patients who concurrently
take anticholinergic medications may not be the best candidates for these drugs.
Similarly, patients with S Jogren's syndrome or dryness of the mouth due to
decreased saliva production may not be good candidates for these tablet
formulations. Although no water is needed to allow the drug to disperse quickly
and efficiently, most technologies utilize the body's own salivation. Decreased
volume of saliva may slow the rate of dissolution/disintegration and decrease the
bioavailability of the product.
Although chewable tablets have been on the market for some time, they
are not the same as the new Orodispersible tablet. Patients for whom chewing is
difficult or painful can use these new tablets easily. Orodispersible tablet can be
used easily in children who have lost their primary teeth, but do not have full use
of their permanent teeth.
Patients may mistake fast-dissolving/disintegrating for effervescent
tablets. Pharmacists may wish to stress the difference between the use of quick-
dissolving and effervescent tablets.
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1.2. REQUIREMENTS OF ORODISPERSIBLE TABLET
An Ideal Orodispersible tablet should:
 Require no water for oral administration, yet dissolve / disperse
disintegrate in mouth in a matter of seconds,
 Have a pleasing mouth feel,
 Have an acceptable taste masking property,
 Be harder arid less friable,
 Leave minimal or no residue in mouth after administration,
 Exhibit low sensitivity to environmental conditions,
 Allow the manufacture of the tablet using conventional processing and
packing equipment.
 Dose lower than 30mg.
 Ability to permeate oral mucosal tissue
DESIRED CRITERIA FOR MOUTH DISSOLVING DRUG DELIVERY
SYSTEM 5,6:
The tablets should
 Not require water to swallow, but is should dissolve or disintegrate in the
mouth in matter of seconds.
 Be compatible with taste masking.
 Be portable with taste masking.
 Have a pleasing mouth feel.
 Leave minimal or no residue in the mouth after oral administration.
 Exhibit low sensitivity to environmental conditions as humidity and
temperature.
 Allow the manufacture of tablet using conventional processing and
packaging equipment at low cost.
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SALIENT FEATURES OF MOUTH DISSOLVING TABLET 5,6:
 Ease of administration to patient who refuses to swallow tablets, such as
pediatric, geriatric and psychiatric patients.
 No need of water to swallow the dosage form, which is highly convenient
feature for patients who are travelling and do not have immediate access to
water.
 Rapid dissolution and absorption of drug, which will produce quick onset
of action.
 Some drugs are absorbed from the mouth, pharynx and esophagus as the
saliva passes down into the stomach, in such cases bioavailability of drugs
is increased.
 Pre-gastric absorption can result in improved bioavailability and as a result
of reduced dosage; improve clinical performance through a reduction of
unwanted effects.
1.3. FORMULATION ASPECTS IN DEVELOPING ODT5
Orally disintegrating tablets are formulated by utilizing several processes,
which differ in their methodologies and the ODTs formed vary in various
properties such as
 Mehanical strength of tablets
 Taste and mouth feel
 Swallowability
 Drug dissolution in saliva
 Bioavailability
 Stability
The major advantages with effervescent formulation approach that it is a
well established, easy to implement and mask the bitter taste of drug9.  The
effervescent system is generally composed of dry acid and dry base, which when
react facilitate a mild effervescent reaction when the tablet contacts saliva.  The
effervescent reaction accelerates the disintegration of tablet through the release of
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carbon dioxide, water and salt.  Due to evolution of carbon dioxide, the bitter taste
of drug is also masked and a pleasant mouth feel is felt.
Direct compression is the easiest method to manufacture mouth dissolving
tablets (MDTs). The great advantage of direct compression is its low
manufacturing cost.  It uses conventional equipment, commonly available
excipients and a limited number of processing steps. In many cases the
disintegrants used have a major role in the disintegration and dissolution process
of fast disintegrating tablets made by direct compression method. The choice of a
suitable type and an optimal amount of disintegrant is important for ensuring a
high disintegration rate.  The addition of other formulation components such as
water-soluble excipients or effervescent agents can further enhance dissolution or
disintegration properties10
1.4. THE VARIOUS PROCESSES EMPLOYED IN FORMULATING
ODTS ARE AS FOLLOWS
Freeze drying or lyophilization
A process, in which water is sublimated from the product after freezing, is
called freeze drying. Freeze-dried forms offer more rapid dissolution than other
available solid products. The lyophilization process imparts glossy amorphous
structure to the bulking agent and some times to the drug, thereby enhancing the
dissolution characteristics of the formulation.
Molding
Tablets produced by molding are solid dispersions. Physical form of the
drug in the tablets depends whether and to what extent, it dissolves in the molten
carrier. The drug can exist as discrete particles or microparticles dispersed in the
matrix. It can dissolve totally in the molten carrier to form solid solution or
dissolve partially in the molten carrier and the remaining particles stay
undissolved and dispersed in the matrix. Disintegration time, drug dissolution
rate and mouth feel will depend on the type of dispersion or dissolution.
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Cotton candy process
This process is so named as it utilizes a unique spinning mechanism to
produce floss-like crystalline structure, which mimic cotton candy. Cotton candy
process involves formation of matrix of polysaccharides or saccharides by
simultaneous action of flash melting and spinning. The matrix formed is partially
recrystallized to have improved flow properties and compressibility. This candy
flos matrix is then milled and blended with active ingredients and exipients and
subsequently compressed to ODT.
Spray drying
Spray drying is a process by which highly porous, fine powders can be
produced.  The composition contains a bulking agent (mannitol and lactose), a
disintegrant (sodium starch glycolate and croscarmellose sodium), an acidic
ingredient (citric acid) and/ or alkaline ingredients (sodium bicarbonate), which
when compressed into tablets show fast disintegration and enhanced dissolution.
Mass extrusion
This technology involves softening the active blend using the solvent,
mixture of water soluble polyethylene glycol using methanol and expulsion of
softened mass through the extruder or syringe to get a cylinder of the product and
cutting into even segments upon heated blade to form tablets.
Sublimation
This method includes the addition of a sublime salt to the tableting
components, compressing the blend and removing the salt by the process of
sublimation.  The active ingredient, a diluent, a sublime salt (camphor/
ammonium bicarbonate), a binder and other excipients are blended and tablets are
prepared. The tablets dissolve within 10-20 seconds and exhibit sufficient
mechanical strength.
Sugar based excipient
Sorbitol, mannitol, dextrose, xylitol, fructose, maltose and polydextrose
have been used as bulking agents.  Because of their high aqueous solubility and
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sweetness, which impart a pleasing mouth feel and good taste masking, nearly all
formulations for rapidly dissolving tablets contain sugar-based materials.
Direct compression
It is the easiest way to manufacture tablets. Conventional equipment, commonly
available excipients and a limited number of processing steps are involved in
direct compression. Directly compressed tablets disintegration and solubilization
depends on single or combined action of disintegrants, water soluble excipients
and effervescent agents. Disintegrant efficacy is strongly affected by tablet size
and hardness. Large and hard tablets have disintegration time more than that
usually required. As a consequence, products with optimal disintegration
properties often have medium to small size and /or high friability and low
hardness. Breakage of tablet edges during handling and tablet rupture during the
opening of blister alveolus, all result from insufficient physical resistance.
Disintegrants have major role in the disintegration and dissolution process of
mouth dissolving tablets made by direct compression. To ensure a high
disintegration rate, choice of suitable type and an optimal amount of disintegrant
is important. Other formulation components such as water soluble excipients or
effervescent agents can further enhance dissolution or disintegration properties.
1.5.DISINTEGRANTS AND MECHANISM OF ACTION
A disintegrant is an excipient, which is added to aid in the breakup of the
compacted mass, when put into a fluid environment.  This is especially important
for immediate release product where rapid release of the product is required.
Disintegration mechanisms are complex processes.  They depend first on the
excipients used, but also on the properties of the active material.
The proposed mechanism of action of disintegrants include:
1. Water uptake through wicking.
2. Swelling
3. Deformation (shape recovery)
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4. Particle repulsion
5. Heat of wetting.
Disintegrants usually work in following ways
1. Wicking Water transport into the tablet.
2. Swelling: Particles absorb water and expand, like a dry sponge, pushing
against the interior of a tablet or capsule causing it to fall apart or discharge its
contents.
3. Elastic recovery: Stored potential energy is released from disintegrant
particles after contact with a fluid environment.
4. Repulsion: Electrostatic forces separate the particles.
Wicking and Swelling
A superdisintegrant has to transport water into the tablet centre very quickly
(capillary) and has to swell itself at the same moment.  As soon as the water
penetrates the tablet, it disrupts interparticular matrix bonds causing the tablet to
fall apart.  To accelerate water transportation, very often powdered cellulose or
microcrystalline cellulose is used.
In the disintegrating tablet, the disintegrant volume increases.  During this
process the space between matrix particles is filled and after very short time, the
particles are separated by the force of the swelling disintegrant.
During swelling, the disintegrant undergoes a deformation that means a
force, which acts against the compressed particles.
Elastic recovery
Most materials, which undergo a plastic deformation during compression,
try to return to their initial shape as soon as possible (stored potential energy).  In
the tablet matrix, there is no means to recover the former shape. But as soon as
water penetrates into the tablet matrix and the forces, which keep the particles
together are diminished, those particles have the ability to expand back.
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In figure-1: elastic particles are shown before compression (red).  After
compression, these particles are plastically deformed.  After penetration of water
into the tablet, these particles return back to their initial shape.
Repulsion:
The principle is that water molecules penetrate a tablet or capsule interior
and generate partial positive and negative charges throughout the matrix.  This
results in the breakdown of particle-particle electrostatic forces of attraction
contributing to matrix breakdown.
The later two mechanisms are not well supported by research.
Water penetration is an indispensable pre-processing step for
disintegration.  The sorption properties of various disintegrants are found to be
essential for efficient disintegration and dissolution.  If the wetting of the super
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disintegrant is slow, for example by coating the disintegrant with a hydrophobic
substance, disintegration of the mass is also slowed.  The extensive research on
super disintegrants has not only implicated the extent of water uptake is important
but also have conclusively demonstrated that the rate of water uptake is of critical
importance for number of disintegrants.
1.6.PATENTED TECHNOLOGIES
Zydis technology
Zydis formulation is a unique freeze dried tablet in which drug is
physically entrapped or dissolved within the matrix of fast-dissolving carrier
material. When zydis units are put into the mouth, the freeze dried structure
disintegrates instantaneously and does not require water to aid swallowing. The
zydis matrix is composed of many materials designed to achieve a number of
objectives. To impart strength during handling, polymers such as gelatin, dextran
or alginates are incorporated. These form a glossy amorphous structure, which
imparts strength. To obtain crystallinity, elegance and hardness, saccharides such
as mannitol or sorbitol are incorporated. Water is used in the manufacturing
process to ensure production of porous units to achieve rapid disintegration.
Various gums are used to prevent sedimentation of dispersed drug particles in the
manufacturing process. Collapse protectants such as glycine prevent the shrinkage
of zydis unit during freeze drying process or long-term storage. Zydis products
are packed in blister packs to protect the formulation from moisture in the
environment.
Lyoc
Oil in water emulsion is prepared and placed directly into blister cavities
followed by freeze-drying. Non-homogeneity during freeze drying is avoided by
incorporating inert filler to increase the viscosity.
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Quick solv
This technology uses two solvents in formulating a matrix, which
disintegrates instantly. Methodology includes dissolving matrix components in
water and the solution or dispersion is frozen. Then dry the matrix by removing
water using excess of alcohol (solvent extraction). Thus the product formed has
uniform porosity and adequate strength for handling.
Nano-crystal technology
Nano-crystal technology includes lyophilization of colloidal dispersions
of drug substances and water soluble ingredients filled into blister pockets. This
method avoids manufacturing process such as granulation, blending and
tableting, which is more advantageous for highly potent and hazardous drugs. As
manufacturing losses are negligible, this process is useful for small quantities of
drugs.
FlashTab technology
This technology involves the preparation of rapidly disintegrating tablet,
which consists of an active ingredient in the form of microcrystals.  Drug
microgranules may be prepared by using the conventional techniques like
coacervation, microencapsulation, extrusion-spheronization or simple pan coating
method.  The microcrystals or microgranules of the active ingredients are added
to the granulated mixture of excipients prepared by wet or dry granulation and
compressed into tablets.
Durasolv technology
The tablets made by this technology consist of a drug, fillers and a
lubricant. Tablets are prepared by using conventional tableting equipment and
have good rigidity. These can be packaged into conventional packaging system
like blisters. Durasolv is an appropriate technology for products requiring low
amounts of active ingredients.
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OraSolv
The system essentially makes tablets that contain the taste masked active
ingredients and an effervescent disintegrating agent, which on contact with
saliva, rapidly disintegrates and releases the active ingredient.  The tablets are
made by direct compression at very low compression forces in order to minimize
oral dissolution time.  The tablets produced are soft and friable.
WOW tab
WOW means without water. This process uses a combination of low
mouldability saccharide (rapid dissolution) and high mouldability saccharide
(good binding property) to obtain a rapidly melting strong tablet.  The active
ingredient is mixed with a low mouldability saccharide (lactose, mannitol) and
granulated with a high mouldability saccharide (maltose, sorbitol) and
compressed into tablets.
Dispersible tablet technology
It offers development of ODT with improved dissolution rate by
incorporating 8-10% of organic acids and disintegranting agents. Disintegants
include starch, modified starches, microcrystalline cellulose, alginic acid, cross-
linked sodium carboxymethyl cellulose and cyclodextrins.
Pharma burst technology
It utilizes the co-processed excipients to develop ODT, which dissolves
within 30-40s.This technology involves dry blending of dug, flavor, lubricant
followed by compession into tablets.
Frosta technology
It utilizes the concept of formulating plastic granules and compressing at
low pressure to produce strong tablets with high porosity. The process involves
usually mixing the porous plastic material with water penetration enhancer and
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followed by granulating with binder .The tablets obtained have excellent hardness
and rapid disintegration time ranging from 15-30s depending on size of tablets
Oraquick
It utilizes taste masking microspheres technology called as micromask,
which provides superior mouth feel, significant mechanical strength, and quick
disintegration/dissolution of product. This form of matrix that protects drug,
which can be compressed with sufficient mechanical strength. Oraquick product
dissolves within few seconds
Ziplets/Advatab
It utilizes water-insoluble ingredient combined with one or more effective
disintegrants to produce ODT with improved mechanical strength and optimal
disintegration time at low compression force.
Flash Dose technology
Flash dose technology has been patented by Fuisz. Nurofen meltlet, a
new form of Ibuprofen as melt-in-mouth tablets. Flash dose tablets consist of self
binding shearform matrix termed as "floss". Shearform matrices are prepared by
flash heat processing.
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LITERATURE REVIEW
1.Gohel29 et al (2004) prepared the mouth dissolved tablets of Nimesulide using
vaccum drying technique. Granules containing Nimesulide, camphor,
crorospovidone and lactose were prepared by wet granulation technique. Camphor
was sublimed from the dried granules by exposure to vacuum. The tablets were
evaluated for % friability, wetting time and disintegration time. In the present
investigation a 32 full factorial design was used to investigate combined effect of
two formulation variables: amount of camphor and amount of superdisintegrant.
The results of multiple linear regression analysis revealed that for obtaining a
rapidly disintegrating dosage form, tablets should be prepared using optimum
concentration of camphor and higher percentage of crospovidone.
2Ahmed S. Zidan30 et al (2006) formulated and optimized mouth dissolving
tablets containing Rofecoxib using solid dispersion. The purpose of the present
investigation was to increase the solubility and dissolution rate of Rofecoxib by
the preparation of its solid dispersion with polyvinyl pyrrolidone K30 (PVP K30)
using solvent evaporation method. For the preparation of Rofecoxib mouth
dissolve tablets, its 1: 9 solid dispersion with PVP K30 was used with various
disintegrants and sublimable materials. The obtained results showed that
dispersion of the drug in the polymer considerably enhanced the dissolution rate.
The drug-to-carrier ratio was the controlling factor for dissolution improvement.
3.Keith J. Simons31 et al (2006) prepared fast-disintegrating sublingual tablets.
Four tablet formulations, A, B, C, and D, containing 0%, 6%, 12%, and 24% of
Epinephrine bitartrate, respectively, and microcrystalline cellulose: low-
substituted hydroxypropyl cellulose (9:1), were prepared by direct compression,
at a range of compression forces. Tablet weight variation, content uniformity,
hardness, disintegration time, wetting time, and friability were measured for each
formulation at each compression force. All 4 tablet formulations at each
compression force were within the USP limits for weight variation and content
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uniformity. At a mean ± SD hardness of ≤ 2.3 ± 0.2 kg, all tablet formulations
passed the USP friability test. At a mean ± SD hardness of ≥ 3.1 ± 0.2 kg, all
tablet formulations resulted in disintegration and wetting times of <10 seconds
and <30 seconds, respectively.
4.Abdelbary32 et al (2004) prepared orally disintegrating tablets using a
hydrophilic waxy binder. The incorporation of Superpolystate® in the
formulation of RDT was realised by means of two different granulation methods:
wet granulation by using an emulsion of this waxy binder as granulating liquid
and melt granulation where the molten form of the binder was used. The potential
of the intragranular addition of croscarmellose sodium as a disintegrating agent
was also evaluated. An improvement in tablet hardness and friability was
observed with both granulation methods where we were able to obtain RDT with
a disintegration time of 40 ± 2 seconds and a hardness of 47.9 ± 2.5N.
5.Koizumi33 et al (1997) presented an invention, which related to rapidly saliva
tablets using sublimation technique. Compressed tablets of Mannitol did not
dissolve in water due to the low porosity. To increase the porosity of tablets
sublimation was done. Tablets were prepared by direct compression containing
mannitol and camphor. A high porosity was achieved due to formation of many
pores due to camphor sublimation. The compressed tablets have high porosity
(approximately 30%) rapidly dissolved within 15 seconds in saliva.
6.Shawn A. Mitchell34 et al studied a compaction process to enhance dissolution
of poorly water soluble drugs using low-viscosity HPMC. The purpose of this
study was to develop a technique to enhance the dissolution rate of poorly water-
soluble drugs with low-viscosity HPMC without the use of solvent or heat
addition. The compaction processes enhanced drug dissolution relative to drug
alone and also relative to corresponding loosely mixed physical mixtures. The
roller compaction and slugging method produced comparable dissolution
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enhancement. The mechanism for dissolution enhancement is believed to be a
microenvironment HPMC surfactant effect facilitated by keeping the HPMC and
drug particles in close proximity during drug dissolution.
7.Abdelbary35 et al (2005) determined the in vitro disintegration profile of rapidly
disintegrating tablets and correlation with oral disintegration. In the present study,
they evaluated the disintegration profile of RDT manufactured by main
commercialised technologies, using the texture analyzer. In order to simulate as
much as possible the oral disintegration of these dosage forms, a new operating
structure was developed. This structure mimics the situation in the patient’s
mouth and provides a gradual elimination of the detached particles during the
disintegration process. Moreover, the oral disintegration time of the same
products was evaluated by 14 healthy volunteers. Results obtained when artificial
saliva at 37oC was employed as disintegration medium were used to correlate the
in vitro and oral disintegration times. Excellent correlation was found and in
addition, we were able to achieve a qualitative measure of the mouth feel by
comparing the thickness of the tablets and the penetration distance obtained from
the disintegration profile.
8.Fukami36 et al (2006) formulated a rapidly disintegration tablet in the oral cavity
using a Glycine as a disintegrant. Wetting time prepared from
carboxymethylcellulose (NS-300) having the hardness of 4kg was 3 seconds.
Tablets containing NS-300 showed fastest disintegration compared to other
formulations. These results suggest that NS-300 possessed excellent wetting
nature and resulted in the rapid disintegration of tablet. Ethenzamide and ascorbic
acid were added to the formulation, and their disintegration behaviors were
evaluated. Ethenzamide did not affect the disintegration property; however,
ascorbic acid prolonged disintegration time. It was suggested that the tablet
formulation containing NS-300 and Glycine was highly applicable to water-
insoluble drug, such as Ethenzamide.
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9.Shirwaiker37 et al (2004) prepared fast disintegrating tablets of Atenolol. The
preparation contained an active ingredient, sugar (mannitol), superdisintegrant
and dicalcium phosphate. Required quantities of each ingredient were weighed,
mixed and prepared the tablets by dry granulation. All the formulation had
disintegration time of less than 70 seconds. Among the three superdisintegrant
Ac-Di-Sol showed the highest efficacy. Formulation containing 10 % Ac-Di-Sol
showed the least disintegration time of 30 ± 2 seconds compare to Explotab and
Polyplasdone XL.
10.Mishra 38 et al (2005) prepared rapidly disintegrating tablets of Valdecoxib.
The poor aqueous solubility of the drug results in variable dissolution rate and
poor bioavailability. In the present, invention tablets were prepared using various
superdisintegrant following direct compression. All formulation showed
disintegration time of less than 60 seconds along with rapid in vitro dissolution.
All the formulation showed more than 70 % dissolution in 30 min.
11.Amin39 et al (2005) presented an invention, which relates to fast disintegration
tablets for oral administration. Taste masked adsorbents of Ofloxacin were
prepared using cationic exchange resins. Taste evaluation of tablets showed
complete masking of the bitterness of Ofloxacin. The taste-masked complex of
the Ofloxacin was further incorporated into mouth dissolve tablets in combination
with Metronidazole benzoate. All the formulation exhibited an in vitro dispersion
time less than 50 seconds.
12.Remon40 et al (1997) prepared the rapidly disintegrating tablets by
lyophillization. Tablets contained hydrochlorothiazide, Maltrodextrin,
hydroxyethylcellulose and gelatin. The solutions were poured into blisters and
freeze dried. Maltrodextrin could be a filler of choice for the production of
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lyophilized tablets as freeze-drying due to amorphous network, which dissolved
in the water with seconds. They evaluated gelatin, xanthan gum and
hydroxyethylcellulose a binding agents in the formulation of freeze dried tablets
with Maltrodextrin as filling agents.
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3.1. AIM AND OBJECTIVE
Aim of the present work is to formulate Cinnarizine Orodispersible tablet by
using solid dispersion technique and different superdisintegrants and evaluating its
characteristics.
Now a day fast dissolving tablets are gaining more importance in the market.
Clinically, histamine H1-receptor antagonists are the most frequently prescribed drugs
in treatment of motion sickness, vomiting, allergic reaction, vertigo and insomnia
.
Conventional Cinnarizine tablets available in market are not suitable where quick
onset of action is required. Besides, the conventional tablets also show poor patient
compliance particularly by the geriatric and pediatric patients who experience difficulty
in swallowing, and by those who are bed ridden or who are traveling and do not have an
easy access of water.
To provide the patients with the most conventional mode of administration, there
was a need to develop rapidly disintegrating dosage form, particularly one that
disintegrants (polymers) and dissolves/disperses in saliva and can be administered
without need of water.
Cinnarizine is practically insoluble in water and its dissolution rate is limited by
its physicochemical properties .For poorly soluble orally administered drugs the rate of
absorption is often controlled by the rate of dissolution. The rate of dissolution can be
increased by increasing the surface area of available drug by various methods
(micronization, complexation, solid dispersion etc). Another prerequisite for the fast
dissolution may be the disintegration time of tablets. Because, faster disintegration
tablets delivers a fine suspension of drug particles and thus, greater dissolution of the
drug.
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Though, fast disintegrating tablets are prepared by many processes direct
compression using superdisintegrants is more preferred method since it is economical
and includes less procedure steps.
3.2. OBJECTIVE
 To study the effect of solid dispersion technique on dissolution rate,
disintegration time and wetting time was studied.
 To study the effect of various superdisintegrants on disintegration of mouth
dissolving tablets.
 To improve the patient compliance by formulating mouth dissolving tablet.
.
.
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4. PLAN OF THE WORK
.








 Construction of Calibration curve
 Preparation of Solid dispersion by solvent evaporation method.
 Selection of method for Mouth Dissolving Tablets.
 Formulation of Mouth Dissolving Tablets with different superdisintegrants.




 Drug content uniformity
 Disintegration time
 Wetting time
 Water absorption ratio
 In-vitro dissolution study
 Stability studies of Mouth Dissolving Tablets as per ICH guidelines.
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5.DRUG AND EXCIPIENT PROFILE
I. CINNARIZINE (DRUG) 62,63,64,65,66







IUPAC Name : (E)-1-(diphenylmethyl)-4-(3-phenylprop-2-enyl) piperazine
Empirical Formula : C26H28N2
Molecular Weight : 368.514 g/mol
Melting Point : 118C to 122C
Solubility : Powder, practically insoluble in water, freely soluble in
methylene chloride, soluble in acetone, slightly soluble in alcohol
and in methanol.
Water  Solubility : 750 mg/L
4.PHYSICAL PROPERTIES63
Description : A white or almost white and tasteless powder
Storage : Store in a well-closed container, protected from light.
5.PHARMACOLOGY
Category64, 65 : Anti-Allergic Agents
Histamine H1-receptor antagonist
Calcium Channel Blockers
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Mechanism of action
Binds to the Histamine H1 receptor and to muscarinic acetylcholine receptors.
Cinnarizine also inhibits contractions of vascular smooth muscle cells by blocking L
type calcium channels. Cinnarizine has also been implicated in binding to dopamine D2
receptors.
Pharmacological actions
Cinnarizine is an antihistamine and a calcium channel blocker. Histamines
mediate a number of activities such as contraction of smooth muscle of the airways and
gastrointestinal tract, vasodilatation, cardiac stimulation, secretion of gastric acid,
promotion of interleukin release and chemotaxis of eosinophils and mast cells.
Competitive antagonists at histamine H1 receptors may be divided into first (sedating)
and second (non-sedating) generation agents. Some, such as Cinnarizine also block
muscarinic acetylcholine receptors and are used as anti-emetic agents. Cinnarizine
through its calcium channel blocking ability also inhibits stimulation of the vestibular
system.
Pharmacokinetics
Cinnarizine is absorbed from the gastro-intestinal tract, peak plasma
concentrations occurring 2 to 4 hours after oral administration. It undergoes metabolism
and half life of 3 to 6 hours. Cinnarizine is excreted in the faeces mainly as unchanged
drug, and in the urine predominantly as metabolites.
After a single 75 mg dose of cinnarizine, peak plasma level of 160 ± 130 ng/ml
occurred after mean time of 3.0 ± 0.45 hours. Plasma concentrations declined with a
half life of 3.04 hours. The mean AUC was 925µg/ml/hr. Less than 20% of isotopically
active Cinnarizine appears in the urine and about 40% in the faeces.
Half life : 3 -6 hrs
Dose : 25 mg to 75 mg (three times in a day)
Indication : Vertigo, Vomiting
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Nausea, Motion sickness
Vestibular symptoms





Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone;
polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer.
Description:
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value
povidones are manufactured by drum drying and occur as plates.
Functional category:
Disintegrant; dissolution aid; suspending agent; tablet binder.
Solubility:
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water;
practically insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration
of a solution is limited only by the viscosity of the resulting solution, which is a
function of the K-value.
Melting point:
Softens at 150°C.
Stability and storage condition:
Povidone darkens to some extent on heating at 150°C, with a reduction in
aqueous solubility. It is stable to a short cycle of heat exposure around 110–130°C;
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Aqueous solutions are susceptible to mold growth and consequently require the
addition of suitable preservatives.
Povidone may be stored under ordinary conditions without undergoing
decomposition or degradation. However, since the powder is hygroscopic, it should be
stored in an airtight container in a cool, dry place.
Incompatibilities:
Povidone is compatible in solution with a wide range of inorganic salts, natural
and synthetic resins, and other chemicals.
The efficacy of some preservatives, e.g. thimerosal, may be adversely affected by
the formation of complexes with povidone.
Safety:
When consumed orally, povidone may be regarded as essentially nontoxic since it
is not absorbed from the gastrointestinal tract or mucous membranes. Povidone
additionally has no irritant effect on the skin and causes no sensitization.
Reports of adverse reactions to povidone primarily concern the formation of
subcutaneous granulomas at the injection site of intramuscular injections formulated
with povidone. Evidence also exists that povidone may accumulate in the organs of the
body following intramuscular injection.
A temporary acceptable daily intake for povidone has been set by the WHO at up
to 25 mg/kg body-weight.
Application:
In tableting, povidone solutions are used as binders in wet-granulation processes.
Povidone is used as a solubilizer in oral and parenteral formulations and has been
shown to enhance dissolution of poorly soluble drugs from solid-dosage forms.
Povidone solutions may also be used as coating agents.
Also used as a suspending, stabilizing, or viscosity-increasing agent in a number
of topical and oral suspensions and solutions. The solubility of a number of poorly
soluble active drugs may be increased by mixing with povidone.
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III.AGAR
Description:
Agar is a dried, hydrophilic, colloidal polysaccharide complex extracted from the
agarocytes of algae of the Rhodophyceae. The structure is believed to be a complex
range of polysaccharide chains having alternating a-(1!3) and b-(1!4) linkages. There
are three extremes of structure noted: namely neutral agarose; pyruvated agarose having
little sulfation; and a sulfated galactan. Agar can be separated into a natural gelling
fraction, agarose, and a sulfated nongelling fraction, agaropectin.
Physical Characteristics:
Agar occurs as transparent, odorless, tasteless strips or as a coarse or fine powder.
It may be weak yellowish-orange, yellowish-gray to pale-yellow colored, or colorless.
Agar is tough when damp, brittle when dry.
Functional Category
Emulsifying agent; stabilizing agent; suppository base; suspending agent;
sustained-release agent; tablet binder; thickening agent; viscosity-increasing agent.
Applications:
Agar is widely used in food applications as a stabilizing agent. In
pharmaceutical applications, agar is used in a handful of oral tablet and topical
formulations. It has also been investigated in a number of experimental pharmaceutical
applications including as a sustained-release agent in gels, beads, microspheres, and
tablets.
It has also been reported to work as a disintegrant in tablets. Agar has been used in
a floating controlled-release tablet; the buoyancy in part being attributed to air
entrapped in the agar gel network. It can be used as a viscosity-increasing agent in
aqueous systems. Agar can also be used as a base for nonmelting, and nondisintegrating
suppositories.
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Agar has an application as a suspending agent in pharmaceutical suspensions.
IV.GUM KARAYA
Gum karaya is an exudates of gum obtained from the trees of Sterculla Urens.
Description:
White .papery bark. Crude gum karaya is in the form of tears of variable size or in
broken irregular pieces. The colour varies from pale yellow to pinkish brown
translucent.
Application and uses:
The major uses of gum karaya is a bulk laxative in view of its ability to form a
mucilaginous gel on contact with water. Low grade gum served as a more efficient
binder in the briquette. Acceleration of settling rates of first carbonation juice in beet
sugar manufacture can be accelerated by the addition of small amount of a dilute
solution of a natural gum such as gum karaya.
It also serves as ales adhesive water absorber.gum karaya acts as an emulsifying
agent and binding agent by absorbing moisture and stored product. Gum karaya acts as




Isapghula is mainly used as a dietary fiber, which is not absorbed by the small
intestine. The purely mechanical action of isapghula mucilage absorbs excess water
while stimulating normal bowel elimination. Although its main use has been as a
laxative, it is more appropriately termed a true dietary fiber and as such can help reduce
the symptoms of both constipation and mild diarrhea. The laxative properties of
isapghula are attributed to the fiber absorbing water and subsequently softening the
stool. At the same time, this added bulk causes the stool to be better formed, which can
reduce symptoms of diarrhea.
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Isapghula is produced mainly for its mucilage content, which is highest in P.
ovata. The term mucilage describes a group of clear, colorless, gelling agents derived
from plants. The mucilage obtained from isapghula comes from the seed coat.
Mucilage is obtained by mechanical milling/grinding of the outer layer of the seed.
Mucilage yield amounts to about 25% (by weight) of the total seed yield. Plantago-seed
mucilage is often referred to as husk, or psyllium husk. The milled seed mucilage is a
white fibrous material that is hydrophilic, meaning that its molecular structure causes it
to attract and bind to water. Upon absorbing water, the clear, colorless, mucilaginous
gel that forms increases in volume by tenfold or more.
Isapghula mucilage possesses several other desirable properties. As a thickener,
it has been used in ice cream and frozen desserts. A 1.5% weight/volume ratio of
isapghula mucilage exhibits binding properties that are superior to a 10%
weight/volume ratio of starch mucilage. The viscosity of isapghula mucilage
dispersions are relatively unaffected between temperatures of 20 and 50 °C (68 and
122 °F), by pH from 2 to 10 and by salt (sodium chloride) concentrations up to 0.15 M.
These physical properties, along with its status as a natural dietary fiber, may lead to
increased use of isapghula by the food-processing industry. Technical-grade isapghula
has been used as a hydrocolloidal agent to improve water retention for newly-seeded
grass areas, and to improve transplanting success with woody plants.
It is suggested that the isabgol husk is a suitable carrier for the sustained release
of drugs and is also used as a gastroretentive carrier due to its swellable and floatable
nature. The mucilage of isabgol is used as a super disintegrant in many formulations.
VI. MICROCRYSTALLINE CELLULOSE (AVICEL 102) 67
Microcrystalline cellulose is partially depolymerised cellulose prepared from
alpha cellulose.
Category: - Pharmaceutical aid (suspending agent, tablet and capsule adjuvant)
Description: - White or almost white powder, odorless.
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Solubility: - Insoluble in water but swells producing a white opaque dispersion or gel,
slightly soluble in dilute sodium hydroxide solution.
Microcrystalline cellulose for direct compression tabletting comes in a number
of grades like PH 101 (original product) & PH 102 (more agglomerated, large particle
size with better fluidity). When compressed, the MCC particles are deformed plastically
due to the presence of slip planes & dislocation. A strong compact is formed due to the
extremely large number of clean surfaces brought in contact during plastic deformation
& the strength of hydrogen bonds formed.
Here Avicel 102 used as diluent cum disintegrant. The mechanism of Avicel 102
is interlocking .The particle size of Avicel 102 is small. The decrease in particle size
increases binding strength and decreases disintegration time so here we used Avicel
102.
MCC is found in the concentration of 10-25% as a filler binder disintegrant
MCC can be used as a disintegrant at a level of 5-15%. The MCC is effective as a
binder in direct compression. Its binding advantages in granulation decrease with an
increase in water addition. MCC is useful as a disintegrant when used in proportion of
at least 5-15%. The disintegration time of tablets of cation exchange resin was reduced
significantly in the presence of MCC.
VII.MANNITOL 67
Synonyms:
Manita, manna sugar, mannite, 1, 2, 3, 5, 6-hexanehexol, pearlitol.
Description:
Mannitol is a hexahydric alcohol related to mannose and is isomeric with
Sorbitol, Mannitol occurs as a white, odourless, crystalline powder, or free flowing
granules. It has a sweet taste, approximately as sweet as sucrose, and imparts a cooling
sensation in the mouth. Microscopically, it appears as orthorhombic needles when
crystallized from alcohol.
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Chemical Name: D-Mannitol.
Functional Category:
Sweetening agent, tablet and capsule diluent, tonicity agent, bulking agent for
lyophilized preparation.
Application:
Mannitol is primarily used as a diluent (10-90%) in tablet formulation where it
is of particular value since it is not hygroscopic and may thus be used with moisture
sensitive active ingredients. Mannitol is commonly used as as excipient in the
manufacture of chewable tablet formulation because of its negative heat of solution,
Sweetness and mouth feel.
Stability and Storage:
It is stable in dry state and in aqueous solution. The bulk material should be
stored in a well-closed container in a cool, dry place.
VIII. ASPARTAME
It occurs as an off white, almost odorless crystalline powder with an intensely
sweet taste.It is used as an intense sweetening agent in beverage products, food
products, and table-top sweeteners, and in pharmaceutical preparations including
tablets, powder mixes, and vitamin preparations. It enhances flavor systems and can be
used to mask some unpleasant taste characteristics; the approximate sweetening power
is 180–200 times that of sucrose.
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IX. PURIFIED TALC
Synonyms:
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate;
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore.
Empirical formula and molecular weight:
Talc is a purified, hydrated, magnesium silicate, approximating to the formula
Mg6(Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and
iron.
Functional category:
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
Applications: Talc is also used as a lubricant in tablet formulations; in a novel powder
coating for extended-release pellets; and as an adsorbant. In topical preparations, talc is
used as a dusting powder, although it should not be used to dust surgical gloves. Talc is
additionally used to clarify liquids and is also used in cosmetics and food products,
mainly for its lubricant properties. Talc was once widely used in oral solid dosage
formulations as a lubricant and diluent.
Stability and storage conditions:
Talc is a stable material and may be sterilized by heating at 160o C for not less
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma
irradiation. Talc should be stored in a well-closed container in a cool, dry place.
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X.MAGNESIUM STEARATE37
Synonyms : Magnesium Octadecanoate, stearic acid magnesium
salt,
Chemical name : Octadecanoic acid magnesium salt.
Structural formula : [CH3(CH2)16COO]2Mg.
Description
It is a fine, white, precipitated or milled, impalatable powder of low bulk
density, having a faint odor of stearic acid and a characteristic taste. The powder is
greasy to touch and adhere to skin.
Functional categories: Tablet and capsule lubricant.
Solubility
Practically in soluble in ethanol, ether, water; slightly soluble in warm benzene
and ethanol.
Stability and storage
It is stable and should be stored in well- closed container in a cool, dry place.
Incompatibilities
Incompatible with strong acids, alkali and iron salts. most alkaloidal salts.
Application :
It is widely used in pharmaceutical formulations. It is used as lubricant in capsule
andTablet manufacture at concentration between 0.25- 5.0 %. It is also used in barrier
cream.
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6. MATERIALS AND METHODS
6.1. MATERIALS
Table No 1: Materials used
SR.
NO. MATERIALS SOURCE
1. Cinnarizine GlaxoSmithKline Pharmaceuticals Ltd.,
Nashik, Maharashtra
2. Agar Gifted by Signet Chemical Corp.
3. Gum karya Gifted by Signet Chemical Corp.
4. Plantago ovata Gifted by Signet Chemical Corp.
5. PVP K30 Sd Fine Chem Limited, Mumbai
6. MCC Gifted by Signet Chemical Corp.
7. Mannitol Strides Arco Labs, Bangalore
8. Magnesium Stearate Nice Chemicals Laboratory
9. Purified Talc Sd Fine Chem Limited, Mumbai
10. Aspartame Medrich Pharmaceuticals, Bangalore
11. Phosphate buffer pH 6.4 Nice Chemicals Laboratory
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Table No 2: Equipment used
Sl.
No. EQUIPMENT MODEL/ SOURCE
1. UV-spectrophotometer 1700 Pharmascope, Shimadzu
2. Digital Balance BL-220H, Shimadzu
3. Digital pH meter Systronic Electronics, Mumbai
4. Dissolution apparatus TDT-06 N, Electrolab, Mumbai
5. IR spectroscopy 1615 series, Perkin-Elmer
6. Hot air oven Tempo Instruments & Equipments,
Mumbai
7. Hardness tester Monsanto Hardness Tester
8. Friability test apparatus Riche Rich Pharma,Mumbai
9. Tablet punching machine Clit, Ahmedabad
10. Stability chamber Osworld JRIC-11, Mumbai
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6.2. METHODOLOGY
6.2.1. Preformulation studies:
A) Identification and characterization of drug:
Preformulation studies are the first step in the rational development of dosage
form of a drug substance. The objective of preformulation studies are to develop a
portfolio of information about the drug substance, so that this information useful to
develop formulation. Preformulation can be defined as investigation of physical and
chemical properties of drug substance alone and when combined with excipients.
Preformulation investigations are designed to identify those physicochemical
properties and excipients that may influence the formulation design, method of
manufacture, and pharmacokinetic-biopharmaceutical properties of the resulting
product71.
i) Organoleptic Characteristics
The color, odor, and taste of the drug were characterized and recorded using





ii .  Melting point:
The melting point of the drug substances was determined by using melting point
apparatus (PMP-D, Veego). The melting point was determined by introducing small
amount of substance in the capillary attached to graduated thermometer and constant
heat was applied with the assembly suspended in the paraffin bath. The drug sample
was tested in temperature range 100-2500C and point at which drug melts was noted.
The melting point is reported in section
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Iii) Solubility:
Solubility of the Cinnarizine was determined in different solvents like water,
0.1 N Hcl, phosphate buffer pH 6.4, alcohol, acetone etc.
iv) IR absorption spectrum:
FT-IR spectra of drug samples were recorded using potassium bromide (KBr)
pellets at resolution of 4cm-1 for its authentication and to study principle peaks using
FT-IR spectrophotometer (FT-IR 8400S, Shimadzu). Dry sample of drug and potassium
bromide was mixed uniformly and filled into the die cavity of sample holder and an IR
spectrum was recorded. The identified peaks were compared with the principle peaks of
reported IR spectrum; thus the samples were authenticated. The FT-IR spectr of
Cinnarizine was observed.
v) UV absorption maxima of Cinnarizine
UV scanning was done in Simadzu double beam UV/VIS spectrophotometer
using 10 µg/ml drug solutions in the wave length range of( 200-400 nm). Phosphate
buffer 6.4 used as a blank.
B) PREPARATION OF CALIBRATION CURVE :
In the present investigation, Cinnarizine was estimated by UV/VIS
spectrophotometry in phosphate buffer (PH 6.4).
 Preparation of stock solution
Cinnarizine (100mg) was accurately weighed and transferred into the 100 ml
standard volumetric flask. It was dissolved in phosphate buffer (PH 6.4) and volume
was made up to the mark (to get a 1000 µg/ml solution). From this 10 ml was pipette
out and then diluted upto 100 ml with phosphate buffer the (PH 6.4) From that solution
again 10 ml pipetted out and diluted upto 100 ml in volumetric flask with phosphate
buffer the (PH 6.4) to get a stock solution of 10µg/ml.
 Preparation of Standard Curve:
From the stock solution 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 ml were transferred to 10
ml standard volumetric flasks and diluted with phosphate buffer the (PH 6.4) upto the
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mark to obtain Cinnarizine concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 µg/ml
respectively.  Absorbance of each solution was measured at 253.5 nm.
C) DRUG – EXCIPIENT COMPATIBILITY:
The selected polymers were characterized by FT-IR spectroscopy and the FTIR
spectra of the pure drug cinnarizine with used excipients like Agar, Gum karaya,
Plantago ovate. Microcrystalline cellulose,  PVP K30, Aspartame, Mannitol etc.
The instrument was operated under dry air purge and the scans were collected at
scanning speed 2 mm/sec with resolution of 4 cm-1 over the region 4000-400 cm-1. The
scans were evaluated for presence of principle peaks of drug, shifting and masking of
drug peaks and appearance of new peaks due to polymer interaction.
6.2.2 DETERMINATION OF FLOW PROPERTIES:
Angle of repose72
The angle of repose of powder was determined by the funnel method. The
accurately weighed powder was taken in a funnel. The height of the funnel was adjusted
in such a way that the tip of the funnel just touches the apex of the heap of the powder.
The powder was allowed to flow through the funnel freely onto the surface. The
diameter of the powder cone was measured and angle of repose was calculated using the
following equation.
θ = tan-1 h / r
Where, h and r are the height and radius of the powder cone, respectively.
Bulk Density
An accurately weighed quantity of powder, which was previously passed
through sieve # 40 [USP] and carefully poured into graduated cylinder. Then after
pouring the powder into the graduated cylinder the powder bed was made uniform
without disturbing. Then the volume was measured directly from the graduation marks
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on the cylinder as ml. The volume measure was called as the bulk volume and the bulk
density is calculated by following formula;
Bulk density = Weight of powder / Bulk volume
Tapped Density 72
After measuring the bulk volume the same measuring cylinder was set into tap
density apparatus. The tap density apparatus was set to 300 taps drop per minute and
operated for 500 taps. Volume was noted as (Va) and again tapped for 750 times and
volume was noted as (Vb).  If the difference between Va and Vb not greater than 2%
then Vb is consider as final tapped volume. The tapped density is calculated by the
following formula
Tapped density = Weight of powder / Tapped volume
Carr’s Index [Compressibility Index] and Hausner’s Ratio72
Carr’s index and Hausner’s ratio measure the propensity of powder to be
compressed and the flowability of powder. Carr’s index and Hausner’s ratio can be
calculated from the bulk and tapped density.
Carr’s index = Tapped density - Bulk density / Tapped density X 100
Hausner’s ratio = Tapped density / Bulk density
Chapter-6 Methodology
Dept of Pharmaceutics 44 J. K. K. Nattaraja College of Pharmacy
6.2.3 Preparation of Solid Dispersion 60:
Preparation of solid dispersions of cinnarizine:
Solid dispersions of Cinnarizine were prepared by solvent evaporation method.
Drug was weighed and taken in a china dish, dissolved in methanol and then carrier was
added (PVP k30 in ratio of 1:3). The solvent was evaporated at room temperature and
dried in hot air oven at 500 C for 4 hours. The resultant mass was passed through sieve
no. 60 and stored in dessicator.
Physical mixture
Physical mixture (PMs)  having the same weight ratio were prepared by thoroughly
mixing appropriate amounts of Cinnarizine and pvp k30 in a morter until a homogenous
mixture was obtained . the result were sieved through a 60# sieve and denoted as PM.
6.2.4 Characterization of solid dispersions of Cinnarizine with PVP K30:
Drug content:
An accurately weighed quantity of solid dispersion equivalent to 25mg
Cinnarizine was taken into 100 ml of volumetric flask. Dissolved in phosphate buffer
pH 6.4 and the volume were made up with the same. An aliquot of the filtrate was
diluted and analyzed spectrophotometrically (UV-1700, Shimadzu Corporation, Japan )
at 253 nm.
Phase solubility studies:
Phase solubility studies were carried out by adding excess of drug (20 mg ) in
screw-capped vials containing 20ml of aqueous solution of different pvp k30
concentration. Then suspensions were continuously stirred on electromagnetic stirrer
at 250 and 37o and 300 rpm for three days (this duration was previously tested to be
sufficient to reach equilibrium). The suspensions were filtered through 0.22µm
membrane filter. The filtrate were suitably diluted and analyzed,
spectrophotometrically, for the dissolved at 253nm.
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Dissolution study
In vitro dissolution studies of CINNARIZINE  in powder form, SDs, and PMs
were performed by using the  USP XXIII type-II dissolution apparatus (Electrolab
TDT-06N) employing a paddle stirrer at 50 rpm.  900 ml of pH 6.4 phosphate buffer
was used as dissolution medium. The temperature of dissolution medium was
maintained at 37  0.5o C throughout the experiment. Samples of dissolution medium
(5ml) were withdrawn for 20 min by means of syringe fitted with pre-filter at known
intervals of time and analyzed for drug release by measuring the absorbance at 253 nm.
The volume withdrawn at each time interval was replaced with fresh quantity of
dissolution medium. Cumulative percent released was calculated and plotted against
time.
6.2.5 Preparation of tablets containing solid dispersions of cinnarizine:
Different   Cinnarizine   mouth dissolving   tablets were prepared according to
the proportion given in table. The raw materials were passed through a screen (40 mesh)
prior to mixing. powdered   1:3 ratio solid dispersion, containing  amount equivalent
to 25 mg Cinnarizine, was mixed with the other excipients and compressed on a
rotator tablet punching machine equipped with flat-faced 10-mm punches. The tablet
weight was adjusted to ~250 mg
Direct compression method23:
Fast dissolving tablets of Cinnarizine were prepared by Direct Compression
method according to the formulae given in the Tables.
All the ingredients were powdered separately and passed through # 60 mesh
sieve separately. The solid dispersion and directly compressible excipient were mixed
by adding small portion of each at a time and blending it to get a uniform mixture and
kept aside. Then the other ingredients were mixed in geometrical order, in an inflated
polyethylene pouch magnesium stearate and talc were added last and the tablets were
compressed using 8 mm flat round punches to get tablets of 250 mg weight.
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Table no 3:Composition of Cinnarizine tablets prepared by direct compression
method
INGREDIENTS(mg) D1 D2 D3 D4 D5 D6 D7 D8 D9
CINNARAZINE solid
dispersion PVP K30(1:3)
100 100 100 100 100 100 100 100 100
AGAR 10 15 20 - - - - - -
GUM KARAYA - - - 10 15 20 - - -
PLANTAGO OVATA - - - - - - 10 15 20
MCC 50 50 50 50 50 50 50 50 50
ASPARTAME 5 5 5 5 5 5 5 5 5
MAGNESIUM
STEARATE
2 2 2 2 2 2 2 2 2
TALC 3 3 3 3 3 3 3 3 3
MANNITOL 80 75 70 80 75 70 80 75 70
TOTAL 250 250 250 250 250 250 250 250 250
The quantity of solid dispersions was taken after calculating the dose based on drug
content of Cinnarizine.
6.3. EVALUATION OF POST COMPRESSION PARAMETERS OF
CINNARIZINE TABLETS
Weight variation:
Twenty tablets were selected at random and average weight was determined.
Then individual tablets were weighed and the individual weight was compared with an
average weight.
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Hardness and Friability
Friability of the tablets was checked by using Roche Friabilator.  The device
subjects a number of tablets to the combined effect of abrasions and shock by utilizing a
plastic chamber that revolves at 25 rpm dropping the tablets from a height of 6 inches
with each revolution.  Pre-weighed sample tablets were placed in the friabilator, which
was then operated for 100 revolutions. Tablets were dusted and reweighed.
Content uniformity test
Ten tablets were weighed and powdered, a quantity of powder equivalent to 10
mg of CINNARIZINE was transferred to a 25 ml volumetric flask and 15 ml water is
added.  The drug is extracted in water by vigorously shaking the stoppered flask for 15
minutes.  Then the volume is adjusted to the mark with distilled water and the liquid is
filtered.  The CINNARIZINE content was determined by measuring the absorbance at
220.2 nm after appropriate dilution. The drug content was calculated using the standard
calibration curve.  The mean percent drug content was calculated as an average of three
determinations.
Disintegration test
Tablets were taken and introduced in each tube of disintegration apparatus, and
the tablet rack of the disintegration apparatus was positioned into a 1-liter beaker
containing 900 ml of distilled water and the time of disintegration was recorded. To
discriminate between the formulations disintegration was done at room temperature and
disk was not used for the study.
In vitro dispersion time
Tablet was added to 10 ml of pH 6.4 phosphate buffer solution at 37  0.5o C.
Time required for complete dispersion of a tablet was measured.
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Wetting time and Water absorption ratio
A piece of tissue paper folded twice was placed in a small petridish (internal
diameter 5 cm) containing 6 ml of water.  A tablet was put on the paper and the time
required for complete wetting was measured, the wetted tablet was then weighed.
Water absorption ratio ‘R’ was determined using following equation








Where, Wa is weight of tablet before water absorption and Wb is weight of tablet
after water absorption
Dissolution study
In vitro dissolution of CINNARIZINE mouth dissolving tablets was studied in
USP XXIII type-II dissolution apparatus (Electrolab TDT-06N) employing a paddle
stirrer at 50 rpm.  900 ml of pH 6.4 phosphate buffer was used as dissolution medium.
The temperature of dissolution medium was maintained at 37  0.5o C throughout the
experiment. One tablet was used in each test. Samples of dissolution medium (5ml)
were withdrawn by means of syringe fitted with pre-filter at known intervals of time
and analyzed for drug release by measuring the absorbance at 253 nm The volume
withdrawn at each time interval was replaced with fresh quantity of dissolution
Figure -2: Schematic representation of wetting time /water
absorption determination
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medium.  Cumulative percent CINNARIZINE released was calculated and plotted
against time.
Stability testing
Accelerated stability studies on promising CINNARIZINE formulations D1 and
D9 were carried out by storing 15 tablets in amber colored rubber stopped vials at
elevated temperature of 40  2o C/755% RH (Stability chamber, Osworld) over a
period of 90 days (3 months).  At intervals of one month, the tablets were visually
examined for any physical changes, changes in drug content and in vitro dispersion
time.
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7. RESULTS AND DISCUSSION
7.1. PREFORMULATION STUDIES:
i)  Organoleptic properties
The color, odor, and taste were performed as per procedure .the result were
illustrated.
ii) Melting point: 118°C   to 122° C
iii) Solubility:
Powder, practically insoluble in water, freely soluble in methylene chloride, soluble in
acetone, slightly soluble in alcohol and in methanol.
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7.2. ESTIMATION OF CINNARIZINE BY UV-METHOD
Figure 7.2: UV absorption spectra of CINNARIZINE in phosphate buffer pH 6.4
Absorption maximum of cinnarizine was found to be 253.5 nm In phosphate buffer pH
6.4.
7.3 PREPARATION OF CALIBRATION CURVE
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Fig No: 7.3 Standard curve of Cinnarizine in phosphate   buffer pH 6.4.
7.4 DRUG EXCIPIENT COMPATIBILITY
Fig No: 7.4 IR spectrum of cinnarizine with pvp k30
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Fig No: 7.5 IR spectrum of cinnarizine with agar
Fig No: 7.6 IR spectrum of cinnarizine with gum karaya
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Fig No: 7.7 IR spectrum of cinnarizine with plantago ovata
Fig No: 7.8 IR spectrum of cinnarizine with mcc
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7.5 DETERMINATION OF FLOW PROPERTIES:
i) Flow properties: (Angle of repose)
ii) Determination of densities
7.6 CHARACTERIZATION OF SOLID DISPERSION OF  CINNARIZINE
i) Drug content













SD 1:1 96.61 PM 1:1 95.45
SD 1:2 97.98 PM 1:2 96.34
SD 1:3 99.32 PM 1:3 98.42
ii) Dissolution studies of solid dispersions and physical mixtures:
The percentage release of cinnarizine  at various time intervals from the physical
mixture and solid dispersions made by using various concentrations of PVP K30 . It is
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in 20 min. In the 20 min SD containing 1:3 of drug and PVP K30 showed better drug
release 99.45% than other ratios of SD’s.
Table No:7.3 In vitro dissolution profile of cinnarizine, physical mixture and solid
dispersions of cinnarizine in pH 6.4 phosphate buffer.
iii) Comparison Study of Solid dispersion
Table No: 7.4 Comparision of solid dispersions
S . No Formulation Cumulative % drug release after
20 min.
1 DRUG 30.56 ± 2.45 %
2 PM 1:1 43.45 ± 2.05 %
3 PM 1:2 47.23 ± 1.67 %
4 PM 1:3 54.73 ± 3.41 %
5 SD 1:1 90.74 ± 1.34 %
6 SD 1:2 96.54 ± 1.40 %




0 0 0 0
2 25.73 37.5 52.6
4 39.64 44.24 56.39
6 46.75 52.83 63.12
8 53.14 58.88 68.56
10 61.59 62.61 73.4
12 67.33 68.83 76.81
14 74.97 71.77 80.25
16 80.07 81.64 86.16
18 83.80 90.13 97.55
20 90.74 96.54 99.47
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Table No: 7.9 Comparision of solid dispersions
iv) FTIR spectroscopy of Solid Dispersions and Physical Mixtures
IR spectrum of solid dispersions 1:1
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IR spectrum of physical mixture 1:1
IR spectrum of solid dispersions 1:2
IR spectrum of  physical mixtures 1:2
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IR spectrum of solid dispersions 1:3
IR Spectrum of Physical Mixtures 1:3
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7.6 PRE-COMPRESSION PARAMETERS OF CINNARIZINE TABLETS

















D1 0.49 0.57 26.40 14.04 1.16
D2 0.48 0.55 26.06 12.72 1.14
D3 0.46 0.53 23.38 13.20 1.15
D4 0.43 0.49 24.72 12.24 1.14
D5 0.41 0.47 24.94 12.76 1.16
D6 0.39 0.44 25.48 11.36 1.12
D7 0.47 0.64 26.21 14.06 1.16
D8 0.51 0.61 25.74 13.11 1.15
D9 0.46 0.56 23.02 13.79 1.14
*Readings are average of 3 determinations
D1 to D9 indicates formulation containing both solid dispersion and super disintegrants.
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7.7. EVALUATION OF CINNARIZINE MOUTH DISSOLVING TABLETS
Table no 7.5: Post compression parameters



















1 D1 3.03 0.05 0.32 32.961.46 81.350.63 247.870.56
2 D2 2.830.05 0.37 33.701.45 83.022.01 247.700.08
3 D3 2.830.05 0.38 32.880.63 80.451.11 248.870.76
4 D4 2.70.10 0.33 32.160.92 89.940.20 248.870.39
5 D5 2.460.05 0.36 30.080.75 87.840.96 247.170.57
6 D6 2.330.05 0.31 28.110.66 90.410.80 247.490.11
7 D7 2.34±0.05 0.33 24.56±0.31 93.410.80 248.870.32
8 D8 2.37±0.05 0.37 24.120.91 95.410.80 248.710.61
9 D9 2.63±0.05 0.32 22.080.52 98.410.80 248.870.53
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ii) Wetting time and water absorption time:





Sec  (± SD)
Water absorption ratio
% ( ± SD)
1 D1 52.480.86 59.332.89
2 D2 54.150.38 57.222.46
3 D3 51.860.30 57.331.12
4 D4 54.690.49 54.711.51
5 D5 56.540.21 63.261.86
6 D6 57.470.26 60.411.93
7 D7 52.330.26 61.470.26
8 D8 51.670.71 63.560.31
9 D9 47.470.56 67.470.26
iii) In-Vitro Disintegration Time of Cinnarizine
Table no 7.7: In-vitro disintegration data
formulation D1 D2 D3 D4 D5 D6 D7 D8 D9
Disintegratio
n time (sec)
33.70 33.65 32.81 30.33 29.65 27.04 25.21 23.59 22.08
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iv) In - vitro dissolution study of Cinnarizine mouth dissolving tablets
Table No 7.8: Dissolution profile of formulation (D1-D3)
















S No Time (min) D1 D2 D3
1 0 0 0 0
2 2 24.31±0.72 28.33±1.16 21.70±0.96
3 4 29.14±0.68 34.27±0.90 27.55±0.68
4 6 33.72±0.85 40.52±0.87 32.86±0.85
5 8 39.47±0.97 47.87±0.73 38.06±0.93
6 10 45.93±0.63 53.05±0.98 44.83±0.97
7 12 55.28±1.08 66.49±1.07 53.63±1.37
8 14 64.85±0.89 77.68±0.67 62.12±0.74
9 16 72.60±0.75 85.10±0.79 69.19±0.92
10 18 79.31±0.90 94.75±0.81 78.27±0.98
11 20 82.73±0.41 97.54±0.11 82.48±0.16
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Table No 7.9: Dissolution profile of formulation (D4-D6)
















S No Time (min) D4 D5 D6
1 2 26.94±0.91 28.33±1.16 21.94±0.91
2 4 32.47±1.12 34.27±0.90 30.47±1.12
3 6 38.31±0.67 41.52±0.38 36.31±0.17
4 8 45.05±0.80 47.87±0.73 45.05±0.08
5 10 52.18±0.76 51.05±0.81 53.18±0.76
6 12 63.80±0.85 61.49±1.07 64.80±0.85
7 14 74.52±0.59 74.68±0.67 72.52±0.59
8 16 85.63±1.20 79.10±0.79 81.63±1.20
9 18 91.70±0.94 93.75±0.81 93.70±0.94
10 20 93.65±0.48 95.47±0.42 95.35±0.75
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Table No 7.10: Dissolution profile of formulation (D7-D9)
















S No Time (min) D7 D8 D9
1 2 23.70±0.96 23.70±0.96 26.94±0.91
2 4 26.55±0.68 27.55±0.97 35.47±1.12
3 6 32.86±0.85 32.86±0.85 42.31±0.67
4 8 38.06±0.93 31.06±0.73 48.05±0.80
5 10 44.83±0.97 49.83±0.37 54.18±0.76
6 12 53.63±1.37 63.63±1.37 67.80±0.85
7 14 62.12±0.74 67.12±0.74 79.52±0.59
8 16 69.19±0.92 73.19±0.92 90.63±1.20
9 18 78.27±0.98 78.67±0.98 98.70±0.94
10 20 81.75±0.15 81.34±0.38 99.43±0.56
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Table No 7. 11 : In Vitro dissolution data of formulations (D1-D9)
Time
(min) D1 D2 D3 D4 D5 D6 D7 D8 D9
2 24.31±0.72 28.33±1.16 21.70±0.96 26.94±0.91 28.33±1.16 21.94±0.91 23.70±0.96 23.70±0.96 26.94±0.91
4 29.14±0.68 34.27±0.90 27.55±0.68 32.47±1.12 34.27±0.90 30.47±1.12 26.55±0.68 27.55±0.97 35.47±1.12
6 33.72±0.85 40.52±0.87 32.86±0.85 38.31±0.67 41.52±0.38 36.31±0.17 32.86±0.85 32.86±0.85 42.31±0.67
8 39.47±0.97 47.87±0.73 38.06±0.93 45.05±0.80 47.87±0.73 45.05±0.08 38.06±0.93 31.06±0.73 48.05±0.80
10 45.93±0.63 53.05±0.98 44.83±0.97 52.18±0.76 51.05±0.81 53.18±0.76 44.83±0.97 49.83±0.37 54.18±0.76
12 55.28±1.08 66.49±1.07 53.63±1.37 63.80±0.85 61.49±1.07 64.80±0.85 53.63±1.37 63.63±1.37 67.80±0.85
14 64.85±0.89 77.68±0.67 62.12±0.74 74.52±0.59 74.68±0.67 72.52±0.59 62.12±0.74 67.12±0.74 79.52±0.59
16 72.60±0.75 85.10±0.79 69.19±0.92 85.63±1.20 79.10±0.79 81.63±1.20 69.19±0.92 73.19±0.92 90.63±1.20
18 79.31±0.90 94.75±0.81 78.27±0.98 91.70±0.94 93.75±0.81 93.70±0.94 78.27±0.98 78.67±0.98 98.70±0.94
20 82.73±0.41 97.54±0.11 82.48±0.16 93.65±0.48 95.47±0.42 95.35±0.75 81.75±0.15 81.34±0.38 99.43±0.56
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The in vitro dissolution study of all formulations (D1-D9) gives maximum drug
release of 99.43% W/V for formulation D9 at the end of 20 min.  all the formulations
were within the limits for various post compression  parameters like hardness, friability,
weight variation and drug content.
Here, D9 given less disintegration time and better drug release after 20 min.
Hence, D9 having  Plantago Ovata as disintegrant  was selected as the best formulation.
7.8 STABILITY STUDY
Optimized formulation D9 was subjected to stability studies 40  20C
/ 75  5% RH for 90 days. The product was evaluated for description, drug
content and in vitro disintegration time. Drug release studies were conducted as
per the procedure.
Descriptions:








40  20C / 75 
5% RH
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Table No 7.13: Stability data of D9 formulation at 40  20C / 75  5% RH
Sl.








1. 1st day (initial) -- 94.36±0.20 22.16±0.92
2. 30th day (1 month) No changes 93.35±0.11 22.36±0.12
3. 60th day (2 month) No changes 93.12±0.13 22.60±0.15
4. 90th day (3 month) No changes 93.10±0.28 22.89±0.16
Average of three determinations; SD- Standard deviation
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7.9. DISCUSSION
 Preformulation Study
In the preformulation study Cinnarizine was characterized for bulk, tapped
density and angle of repose. Results of the compressibility index, Hauser’s ratio and
angle of repose show that the all material has sufficient compressibility and flow
properties.
 Compatibility Study
Compatibility studies were performed using IR spectrophotometer. The IR
spectrum of pure drug and physical mixture of drug and superdisintegrant were studied.
The characteristic absorption peaks of Cinnarizine were obtained at 2308cm-1, 2503cm-
1
, 3053cm-1, 3358cm-1and 3772cm-1.The peaks obtained in the spectrum of each
formulation correlates with the peaks of pure drug of Cinnarizine. This indicates that the
drug was compatible with the formulation components.
 Analytical Method
Analytical method suitable to determine the contents of Cinnarizine was done
by UV Spectroscopically. Cinnarizine shows the absorption maxima at 253.5 nm in
0.1N HCl (Ph 6.4) and absorption was linear through 1µg/ml to 10µg/ml. This method
was found to be accurate, precise and specific for Cinnarizine.
 Selection of Tabletting Methodology
Effervescent method, Superdisintegrants addition method were tried for
formulation of mouth dissolving tablets by direct compression technique. Super
disintegration addition method exhibits the lowest disintegration time, hence it was
concluded as the best method than compare to remaining methods.
 Discussion of the effect of concentration Crosspovidone in the trial series.
Batch D9 (10% plantago ovata) has lowest disintegration time (22.08 sec) than
other batches but % friability is very high (0.39 %) and not in IP limit. Batch D7, D8
and D9 has0.36%,0.37% and0.39% friability in IP limit, from that D9 exhibits the
lowest disintegration time, hence it was the best batch as compare to remaining
batches.
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 Discussion of the characterization of the mouth dissolving tablets of
Cinnarizine with various super disintegrants
Agar , Gum karaya and Plantago ovata were tried for formulation of mouth
dissolve tablets. The concentration of superdisintegrant was taken 4%, 6% and 10 %.
The powder blend was evaluated for angle of repose, hausner’s ratio and %
compressibility. The prepared tablet was evaluated for physical parameter, Wetting
time, In vitro disintegration time, Assay and In vitro drug release.
 Evaluation of powder blend:
1. Angle of Repose ()
The angle of repose for the entire formulations blend was found to be in the
range 23.02o to 26.40o. Formulations with Plantago ovata and Gum karaya as a
disintegrants showed angle of repose values ≤ 30o where as formulation containing
Agar showed angle of repose values > 30o indicating only fair flow property of the
powder blend.
2. Hausner ratio
Hausner ratio was found to be in the range 1.12 to 1.16 and that indicated that
all formulation has good flow properties.
3. Carr’s index
Carr’s index was found to be in the range 11.36% to 14.06% that indicated all
formulation has good flow properties.
 Physical Parameters
1. Weight variation
All the formulated (D1 to D9) tablets were passed weight variation test as the %
weight variation was within the IP limits of 7.5% of the weight. The weights of all the
tablets were found to be uniform with low standard deviation values. The prepared
formulation complies with the weight variation test.
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2.Hardness
The hardness of the tablet was found to be 2.3 to 3.0 Kg/cm2
3. Friability test
The maximum friability of the formulation was found to be 0.38%. The
minimum friability of the formulation was found to be 0.31%. The % friability was less
than 1% in all the formulations ensuring that the tablets were mechanically stable.
4. Drug content
The maximum drug content for the all formulation was found to be 98.41% and
minimum % drug content from the all formulation was found to be 81.35%. The results
were within the limit specified by the IP.
5. In vitro Disintegration test
In vitro Disintegration time was found to be in the range 22.08 to 33.70 sec.
From all formulations, D9 (10% plantago ovata) has minimum disintegration time 22.08
sec. Formulations containing agar has taken more time for disintegration because of its
gelling properties.
6. Wetting Time
Wetting Time was found to be in the range 47.47 to 57.47 sec. From all
formulations, D9 (10% plantago ovata) has minimum wetting time.
7. In vitro drug release
All the 9 formulations were subjected to in vitro dissolution studies by using
0.1N HCl. Dissolution data shows that formulation D9 having having 10 %( Plantago
ovata) gave improved dissolution as compared to other formulations and total drug
release of  99.43% was found at 20 min
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 Stability Study
Stability study was carried out for the optimized formulation according to ICH
guide lines at 40±2° C (controlled sample), Room temperature and 40° C for 3 months.
The results showed that there was no significant change in physical and
chemical parameter of the tablet, hence the formulation was found to be stable.
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8. SUMMARY AND CONCLUSION
Cinnarizine is a histamine H1-receptor antagonist is the most frequently
prescribed drug in treatment of motion sickness, vomiting, allergic reaction, vertigo and
insomnia. Conventional Cinnarizine tablets available in market are not suitable where
quick onset of action is required. To overcome these problems, there is a need to
develop a rapidly disintegrating dosage form, particularly one that would rapidly
disintegrate in saliva and could be administered without water anywhere anytime. No
such mouth dissolving tablet of Cinnarizine is available in the market.
In the present work, Mouth dissolving tablets were prepared by Effervescent,
Superdisintegrant addition and evaluated for disintegration time, hardness and friability.
The Mouth dissolving tablets of Cinnarizine were prepared by
superdisintegrants addition method using agar ,gum karaya and plantago ovate in
different concentration like 4%, 6% and 10%. There are total nine formulations were
prepared and evaluated for Weight variation, Thickness, Friability, Hardness,
Disintegration time, Wetting time, Assay and In-vitro dissolution study.
The results of all formulations for Weight variation, Friability, Hardness and
Assay were found to be within the IP limit and no significant variation. The Dispersion
time for all formulations was found to be 22 to 33.70 seconds and wetting time was
between 47.47 to 56.54 seconds. Based on the In-vitro dissolution studies, it was found
that the drug release for all the formulations were within 30 minutes.
Formulation D9 containing plantago ovata in concentration of 10% showed
minimum disintegration time, wetting time as compare to other formulations.
Dissolution studies conclude that the total drug was released within 6 minutes. The
results shown that disintegration time was increased in the following manners
Plantago Ovata < Gum Karaya < Agar.
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The stability studies were performed for formulation D9 as per I.C.H
guidelines, for its in-vitro disintegration time, wetting time and in-vitro drug release
pattern. The formulation showed no significant variations for the above mentioned
parameters and it was stable for the specified time period.
It was concluded that the mouth dissolving tablet of Cinnarizine can be
formulated by superdisintegrant addition technique using Plantago ovate, Gum Karaya
and agar in different concentrations.
Chapter-9 Bibliography
Dept of Pharmaceutics 75 J. K. K. Nattaraja College of Pharmacy
BIBLIOGRAPHY
1) Brahmankar D. M., Jaiswal S.B., Biopharmaceutics & Pharmaceutics, First Edition,
1995, 335.
2) Howard C. Ansel, Nicholas G. Popvich, Loyd V. Allen, Pharmaceutical Dosage
Forms and Drug Delivery System, First Edition, 1995, 78.
3) S. S. Biradar, S. T. Bhagavati and I. J. Kuppasad, Fast Dissolving Drug Delivery
Systems: A Brief Overview, Internet J. Pharmacology, 2006, 4(2).
4) Kuccherkar B.S., Badhan A.C., Mahajan H.S., Mouth dissolving tablets: A novel
drug delivery system, Phrma Times, 2003, 35, 3-10.
5) Kaushik D, Dureja H., Saini T. R., Mouth Dissolving Tablets: A review, Indian
Drugs, 2004, 41(4), 187-193.
6) Amin A. F., Shah T. J., Bhadani M. N., Patel M. M., Emerging trends in orally
disintegrating tablets, www.pharminfo.net, 2005.
7) Renon J. P. and Corveleyn S., Freeze-dried rapidly disintegrating tablets, US Patent
No. 6,010,719, 2000.
8) Lailla J. K., Sharma A. H., Freeze-drying and its applications, Indian Drugs, 1993,
31, 503-513.
9) Seager H., Drug delivery products and zydis fast dissolving dosage form, J. Pharm.
Phamacol., 1998, 50, 375-382.
10) Masaki K., Intrabuccaly disintegrating preparation and production, US Patent No.
5,466,464, 1995.
11) Pebley W. S., Jager N. E. and Thompson S. J., Rapidly disintegrating tablets, US
Patent No.  5,298,261, 1994.
12) Allen L. V. and Wang B., Method of making a rapidly dissolving tablet, US Patent
No. 5,635,210, 1997.
Chapter-9 Bibliography
Dept of Pharmaceutics 76 J. K. K. Nattaraja College of Pharmacy
13) Allen L. V. and Wang B., Process for making a particulate support matrix for
making rapidly dissolving tablets, US Patent No. 5,587,180, 1996.
14) Heinmann H. and Rothe W., Preparation of porous tablets, US Patent No.
3,885,026, 1975.
15) Knistch K.W., Production of porous tablets, US Patent No. 4,134,843, 1979.
16) Roser B. J. and Blair J., Rapidly soluble oral dosage form, method of making same
and composition, US Patent No. 5,762,961,1998.
17) Lachmann L., Liebermann H. A. and Kiang J.L., The theory and practice of
Industrial Pharmacy, Third Edition, Varghese Publishing House, Bombay, 1998,
430-440.
18) Yarwood R. J., Kearny K. and Thomson A.R., Process for preparing solid dosage
form for unpalatable pharmaceuticals, US Patent No. 5,738,875, 1998.
19) Parul B. Patel, Amit Chaudhary and G. D. Gupta, Fast Dissolving Drug Delivery
Systems: An Update, www.pharmainfo.net, 2006.
20) Suresh B. Borsadia, David Halloran and James L. Osborne, Quick-dissolving films
– A novel approach to drug delivery, www.drugdeliverytech.com, 2006.
21) Mishra B., Panigrahi D. and Baghel S., Mouth dissolving tablets: an overview of
preparation techniques, evaluation and patented technologies, J. Pharm. Res., 2005,
4(3), 33-38.
22) Gregory G. K. E., Peach G. M. and Dumanya J. D., Method for producing fast
dissolving dosage form, US Patent No. 4,371,561, 1983.
23) Mizumoto T., Masuda Y. and Fukui M., Intrabuccaly dissolving compressed
moldings and production process, US Patent No. 5,576,014, 1996.
24) Robin H. Bogner and Meghan F. Wilkosz, Fast-Dissolving Tablets,
www.uspharmacist.com, 2006.
25) Bhaskaran S. and Narmada, G. V., Orally disintegrating tablets, Indian Pharmacist,
2002, 1(2), 9-12.
Chapter-9 Bibliography
Dept of Pharmaceutics 77 J. K. K. Nattaraja College of Pharmacy
26) Tablets: Formulation of tablets/Disintegration, www.pharmpedia.com, 2006.
27) Shah U. and Augsburger L., Evaluation of the functional equivance of
crospovidone NF from different sources: standard performance test, Pharm.
Develop. Tech., 2001, 6, 419-430.
28) Swarbrick J., Boylan J., Encyclopedia of Pharmaceutical technology; 2nd Ed.,
Marcel Dekker, NY, 2002, 2623-2638.
29) Gohel M., Patel M., Amin A., Agrwal R., Dave R. and Bariya, N., Formulation
design and optimization of mouth dissolve tablets of nimesulide using vaccum
drying technique, AAPS Pharm SciTech, 2004, 5(3), 1-6
30) Omaima A. Sammour, Mohammed A. Hammad, Nagia A. Megrab and Ahmed S.
Zidan., Formulation and optimization of mouth dissolve tablets containing rofecoxib
solid dispersion, AAPS Pharm SciTech, 2006, 7 (2) Article 55.
31) Mutasem M. Rawas-Qalaji, F. Estelle R. Simons and Keith J. Simons., Fast-
disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics,
AAPS Pharm SciTech, 2006, 7 (2) Article 41.
32) G. Abdelbary, P. Prinderre, C. Eouani, J. Joachim, J.P. Reynier and Ph. Piccerelle.,
The preparation of orally disintegrating tablets using a hydrophilic waxy binder, Int.
J. Pharm., 2004, 278, 423–433.
33) Kei-ichi Koizumi, Yoshiteru Watanabe, Kumiko Morita, Naoki Utoguchi and
Mitsuo Matsurnoto, New method of preparing high-porosity rapidly saliva soluble
compressed tablets using mannitol with camphor, a subliming material, Int. J.
Pharm., 1997, 152, 127-131.
34) Shawn A. Mitchell, Thomas D. Reynolds and Tina P. Dasbach, A compaction
process to enhance dissolution of poorly water soluble drugs using hydroxypropyl
methylcellulose, Int. J. Pharm., 2003, 250, 3-/11.
35) G. Abdelbary., C. Eouani, P. Prinderre, J. Joachim, Jp. Reynier and Ph. Piccerelle,
Determination of the in vitro disintegration profile of rapidly disintegrating tablets
and correlation with oral disintegration, Int. J. Pharm., 2005, 292, 29–41.
Chapter-9 Bibliography
Dept of Pharmaceutics 78 J. K. K. Nattaraja College of Pharmacy
36) Fukami J., Yonemochi E., Yoshihashi Y. and Terada K., Evaluation of rapidly
disintegrating tablets containing glycine and carboxymethylcellulose, Int. J. Pharm.,
2006, 9, 101-109.
37) Shirwaiker A. A. and Ramesh M., Fast disintegrating tablets of Atenolol by dry
granulation method, Indian J. Pharm. Sci., 2004, 66, 422-426.
38) Mishra D. N., Bindal M., Singh S. K. and Kumar S. G. V., Rapidly disintegrating
tablets of valdecoxib, Indian Drugs, 2005, 42, 685-687.
39) Amin P. D., Gupta S. S., Prabhu N. B. and Wadhwani A. R., Fast disintegrating
dosage form of ofloxacin and metrobenzole benzoate, Indian Drugs, 2005, 42, 614-
617.
40) Remon J. P. and Corveleyn S., Formulation and production of rapidly disintegrating
tablets by lyophiliization using hydrochlorothiazide as a model drug, Int. J. Pharm.,
1997, 152, 215-225.
41) Chaudhari P. D., Khole S. R., Dave K. V. and More D. M., Formulation and
evaluation of fast dissolving tablets of famotidine, Indian Drugs, 2005, 42, 641-649.
42) Vijaya K. S. G. and Mishra D. N., Rapidly disintegrating oral tablets of meloxicam,
Indian Drugs, 2006, 43, 117-121.
43) Sreenivas S. A., Gadad A. P. and Patil M. B., Formulation and evaluation of
ondansetron HCl directly compressed mouth disintegrating tablets, Indian Drugs,
2006, 43, 35-38.
44) Aithal K., Harish N. M., Rathanand M., Shirwaikar A. and Dutta M., Once daily
fast dissolving tablets of Granisetron hydrochloride- formulation and invitro
evaluation, Indian Drugs, 2006, 43(7), 576- 581.
45) Dandagi P. M., Halakatti P. K., Masthiolimath V. M., Patil M. B. and Manvi F. V.,
Rapidly disintegrating domperidone tablets, Indian Drugs, 2006, 43(7), 594-597.
46) Kuchekar B. S., Badhan A. C. and Mahajan H. S., Mouth dissolving tablets of
salbutamol sulphate: A novel drug delivery system, Indian Drugs, 2004, 41(10),
592-598.
Chapter-9 Bibliography
Dept of Pharmaceutics 79 J. K. K. Nattaraja College of Pharmacy
47) Nayak S. M. and Gopalkumar P., Design and optimization of fast dissolving tablets
for promethazine theoclate, Indian Drugs, 2004, 41(9), 554-556.
48) Kaushik D., Dureja H. and Saini T. R., Formulation and evalution of olanzapine
mouth dissolving tablets by effervescent formulation approach, Indian Drugs, 2004,
41(7), 410-412.
49) Devi V. K., Asha A. N., Pai R. S. Reddy M. C. H. and Raghvendra M. M. A. V.,
Oral dispersible fluconazole tablets - Preparation and evaluation, Indian Drugs,
2006, 43(7), 548-552.
50) H. S. ahajan, B. S. Kuchekar and A. C. Badhan, Mouth dissolve tablets of
sumatriptan succinate, Indian J. Pharm. Sci., 2004, 66(3), 238- 240.
51) D. M. Patel, N. M. Patel, R. R. Shah, P. D. Jogani and A. I. Balapatel, Studies in
formulation of orodispersible tablets of rofecoxib, Indian J. Pharm. Sci., 2004,
66(5), 621-625.
52) S. A Desai, S. V. Ferade, K. C. Petkar, D. S. Kuchkar, Orodissolving tablets of
promethazine hydrochloride, Ind. J. Pharm. Edu. Res., 2006, 40(3), 172-174.
53) M. M. Patel and D. M. Patel, Fast dissolving valdecoxib tablets containing solid
dispersion of valdecoxib, Indian J. Pharm. Sci., 2006, 68(2), 222-226.
54) Poornima D. Amin, Anita R. Wadhwani and Namita B. Prabhu, Patient compliant
dosage form for Roxithromycin, Indian J. Pharm. Sci., 2004, 66(5), 670- 673.
55) Purnima Amin, Namita Prabhu and Anita Wadhwani, Indion 414 as super
disintegrating in formulation of mouth dissolve tablets, Indian J. Pharm. Sci., 2006,
68(1), 117-119.
56) Mane Avinash R. and Kusum Devi V., A novel technique for the preparation of
mouth dissolving tablets of domperidone, Indian Drugs, 2003, 40(9), 544-546.
57) Shishu and Bhatti A., fast disintegrating tablets of diazepam, Indian Drugs, 2006,
43(8), 643- 648. s
Chapter-9 Bibliography
Dept of Pharmaceutics 80 J. K. K. Nattaraja College of Pharmacy
58) Gordan M. S., Rudraraju V. S., Rhie J. K. and Chowan Z. T., The effect of aging on
the dissolution of wet granulated tablets containing super disintegrants, Int. J.
Pharm., 1993, 97, 119-131.
59) Machida Y., Inouye K., Tokumura T., Iwata M. and Nagai T., Preparation and
evaluation of intragastric buoyant preparations, Drug Des. Deliv., 1989, 4, 155-161.
60) J. M. Gines, M. D. Veiga, M. J. Arias and A.M. Rabasco, Elaboration and thermal
study of interactions between cinnarizine and gelucire® 53/10 physical mixtures
and solid dispersions, Int. J. Pharm., 1995, 126, 287-291.
61) Greg A. Kossena, William N. Charman, Ben J. Boyd and Christopher J. H. Porter,
A novel cubic phase of medium chain lipid origin for the delivery of poorly water
soluble drugs, J. Control. Release, 2004, 99, 217–229.
62) Cinnarizine, www.redpoll.pharmacy.ualberta.ca/drugbank/index.html, 2006.
63) British Pharmacopoeia, Cinnarizine, The Stationery Office on behalf of the
Medicines and Healthcare products Regulatory Agency (MHRA),2001, 398- 400.
64) James E F Reynolds: Martindale, The extra Pharmacopoeia, Thirty-First edition,
Royal Pharmaceutical Society, London, 1996, 406.
65) Cinnarizine: drug information, www.emc.medicines.org.uk, 2006.
66) CIMS-93 April-2006 (update-2), 211-212.
67) Handbook of Pharmaceutical Excipient Third Edition, Edited by Arthur H. Kibbe,
102-103.
68) Information of suerdisintegrants, www.pformulate.com, 2006.
69) Crospovidone, www.nppharm.fr.com, 2006.
70) Herbert A. Liberman and Leon Lachman, The Theory and Practice of Industrial
Pharmacy, Third Edition, Verghese Publication House, 171, 293.
71) Cooper J, Gun C, Powder Flow and Compaction, Tutorial Pharmacy, New Delhi,
hidix CBS Publishers and Distributors, 1986, 211-233.
Chapter-9 Bibliography
Dept of Pharmaceutics 81 J. K. K. Nattaraja College of Pharmacy
72) Indian Pharmacopoeia, Fourth Edition, controller of Publication., Govt. of India.,
New  Delhi, 1996, A-86.
73) Kulkarni G T, Gowathamarajan K, Suresh B, Stability testing of Pharmaceutical
product: an overview, Ind. J. Pharm. Sci., 2004, 38(4), 194-202.
74) ICH Q1A (R2), Stability Testing Guidelines, Stability testing of a new drug product
and new drug substance.
